Drug resistant superbugs are killing 33,000 in Europe each year

Published On 2018-11-09 05:27 GMT | Update On 2018-11-09 05:27 GMT

LONDON - Superbug infections resistant to multiple antibiotics kill around 33,000 people a year in Europe, health experts said on Monday, and the burden of these diseases is comparable to that of flu, tuberculosis and HIV combined.

An analysis by the European Centre for Disease Prevention and Control (ECDC) found the impact of drug-resistant infections had increased since 2007, with concerning rises in cases of bugs resistant to even the most powerful, last-resort antibiotics - including a class of drugs known as carbapenems.

"This ... is worrying because these antibiotics are the last treatment options available," the ECDC said in a statement. "When these are no longer effective, it is extremely difficult or, in many cases, impossible to treat infections."

Specialists estimate that around 70 per cent of bacteria that can cause infection are already resistant to at least one antibiotic that is commonly used to treat them.

This has made the evolution of "superbugs" that can evade one or multiple drugs one of the biggest threats facing medicine today.

The ECDC study, published in the Lancet Infectious Diseases journal, focussed on five types of infections caused by antibiotic-resistant bacteria in the European Union and in the European Economic Area (EU/EEA).

It found that around 75 per cent of the burden of superbug disease is due to infections contracted in hospitals and health clinics - known as healthcare-associated infections (HAIs).

"Strategies to prevent and control antibiotic-resistant bacteria require coordination at EU/EEA and global level," it said. It added that due to variations in the numbers of cases and the types of antibiotic-resistant bacteria causing infection in different countries, prevention and control measures need to be tailored to national situations.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Drug resistant superbugs are killing 33,000 in Europe each year

Similar News

'Indians are bad': Florida patient attacks Indian-origin nurse, breaks almost every bone on her face

Frailty tied to Adverse Events in RA Patients on Biologic and Targeted Synthetic DMARDs, finds study

High dietary acid load can potentially worsen cardiometabolic risk factors, study reveals

Diabetes stigma tied to food insecurity, disordered eating and lower psychosocial well-being in diabetes patients: Study

Physical Activity may ease symptom burden of postconcussion in children, suggests study

Strength training improves knee health, lowers risk of knee osteoarthritis: Study

Sibling death in childhood tied to increased risk of early-onset cardiovascular disease: JAMA

Bisoprolol safe and effective for treating chronic obstructive pulmonary disease: Study